SCHEMBL25368673

SCHEMBL25368673

CC(=O)N1C(=S)NC(=O)C1Cc1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
GAA P10253 1/20 0.43
HIF1A Q16665 1/20 0.43
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
CACNA1F O60840 2/20 0.38
CACNA1D Q01668 2/20 0.38
CACNA1S Q13698 2/20 0.38
CACNA1C Q13936 2/20 0.38
ALDH1A1 P00352 5/20 0.38
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
LMNA P02545 1/20 0.37
CES2 O00748 1/20 0.36
HSD17B10 Q99714 1/20 0.34
MAPK1 P28482 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25367152 0.79 NPSR1 (0.46) MAPTNPSR1MEN1POLBKMT2A
SCHEMBL25368489 0.78 MAPT (0.52) HPGDMAPTGAAMEN1POLB
SCHEMBL25368484 0.78 MAPT (0.52) HPGDMAPTGAAMEN1POLB
SCHEMBL25367134 0.78 KMT2A (0.41) MAPTNPSR1MEN1KMT2ACACNA1F
SCHEMBL25367130 0.78 KMT2A (0.41) MAPTNPSR1MEN1KMT2ACACNA1F
SCHEMBL25366122 0.75 ALDH1A1 (0.43) MEN1POLBKMT2AALDH1A1LMNA
SCHEMBL25366861 0.75 ALDH1A1 (0.38) MAPTNPSR1GAAMEN1KMT2A
SCHEMBL25366849 0.74 HSD17B10 (0.46) HPGDMAPTMEN1KMT2AALDH1A1
SCHEMBL25367741 0.74 MEN1 (0.42) MAPTNPSR1GAAMEN1KMT2A
SCHEMBL25363327 0.73 BRD4 (0.42) MEN1POLBKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 US disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 EP disclosed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 HPGD 1484/4885MAPT 4710/4885NPSR1 727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.